27-hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen

被引:307
作者
Umetani, Michihisa
Domoto, Hideharu
Gormley, Andrew K.
Yuhanna, Ivan S.
Cummins, Carolyn L.
Javitt, Norman B.
Korach, Kenneth S.
Shaul, Philip W.
Mangelsdorf, David J.
机构
[1] Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA
[3] Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA
[4] NYU, Sch Med, Dept Pediat, New York, NY 10016 USA
[5] NYU, Sch Med, Dept Med, New York, NY 10016 USA
[6] NIEHS, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA
关键词
D O I
10.1038/nm1641
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The cardioprotective effects of estrogen are mediated by receptors expressed in vascular cells. Here we show that 27- hydroxycholesterol ( 27HC), an abundant cholesterol metabolite that is elevated with hypercholesterolemia and found in atherosclerotic lesions, is a competitive antagonist of estrogen receptor action in the vasculature. 27HC inhibited both the transcription- mediated and the non- transcription- mediated estrogen- dependent production of nitric oxide by vascular cells, resulting in reduced estrogen- induced vasorelaxation of rat aorta. Furthermore, increasing 27HC levels in mice by diet- induced hypercholesterolemia, pharmacologic administration or genetic manipulation ( by knocking out the gene encoding the catabolic enzyme CYP7B1) decreased estrogen- dependent expression of vascular nitric oxide synthase and repressed carotid artery reendothelialization. As well as antiestrogenic effects, there were proestrogenic actions of 27HC that were cell- type specific, indicating that 27HC functions as an endogenous selective estrogen receptor modulator ( SERM). Taken together, these studies point to 27HC as a contributing factor in the loss of estrogen protection from vascular disease.
引用
收藏
页码:1185 / 1192
页数:8
相关论文
共 50 条
[1]  
Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012
[2]  
Brouchet L, 2001, CIRCULATION, V103, P423
[3]   Oxysterols and atherosclerosis [J].
Brown, AJ ;
Jessup, W .
ATHEROSCLEROSIS, 1999, 142 (01) :1-28
[4]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[5]   Estrogen modulation of endothelial nitric oxide synthase [J].
Chambliss, KL ;
Shaul, PW .
ENDOCRINE REVIEWS, 2002, 23 (05) :665-686
[6]   Nitric oxide in excitable tissues: Physiological roles and disease [J].
Christopherson, KS ;
Bredt, DS .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (10) :2424-2429
[7]  
Clark James H, 2006, Nucl Recept Signal, V4, pe023
[8]   Controversies about HRT - lessons from monkey models [J].
Clarkson, TB ;
Appt, SE .
MATURITAS, 2005, 51 (01) :64-74
[9]   MENOPAUSE AND THE RISK OF CORONARY HEART-DISEASE IN WOMEN [J].
COLDITZ, GA ;
WILLETT, WC ;
STAMPFER, MJ ;
ROSNER, B ;
SPEIZER, FE ;
HENNEKENS, CH .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (18) :1105-1110
[10]   Characterization of the hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) null mice reveals hypergonadism and endocrine sex reversal in females lacking ERα but not ERβ [J].
Couse, JF ;
Yates, MM ;
Walker, VR ;
Korach, KS .
MOLECULAR ENDOCRINOLOGY, 2003, 17 (06) :1039-1053